Analysts Set Expectations for Annexon FY2025 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Annexon in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings of ($1.47) per share for the year, down from their previous forecast of ($0.99). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share.

Other analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Annexon presently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Trading Down 2.9 %

NASDAQ:ANNX opened at $2.68 on Thursday. The stock has a fifty day moving average price of $3.85 and a 200 day moving average price of $5.38. Annexon has a 12-month low of $2.30 and a 12-month high of $8.40. The firm has a market cap of $285.67 million, a PE ratio of -2.55 and a beta of 1.14.

Annexon (NASDAQ:ANNX) last released its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05).

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Creative Planning boosted its stake in shares of Annexon by 29.5% in the third quarter. Creative Planning now owns 34,779 shares of the company’s stock valued at $206,000 after buying an additional 7,914 shares in the last quarter. GSA Capital Partners LLP increased its holdings in shares of Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after purchasing an additional 3,355 shares in the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Annexon by 3.1% in the third quarter. Mutual of America Capital Management LLC now owns 659,254 shares of the company’s stock valued at $3,903,000 after purchasing an additional 19,681 shares during the period. Intech Investment Management LLC acquired a new position in Annexon during the third quarter worth about $154,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in Annexon by 9.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,160,886 shares of the company’s stock valued at $6,872,000 after buying an additional 96,085 shares in the last quarter.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.